HDL-c is a powerful lipid predictor of cardiovascular diseases

International Journal of Clinical Practice

Volumn 61, Issue 11, 2007, Pages 1905-1913

  Bruckert, E ^a   Hansel, B ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; ETC 216; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRAVASTATIN; RIMONABANT; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; EPIDEMIOLOGICAL DATA; HUMAN; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SITTING; SMOKING; STRUCTURE ANALYSIS;

APOLIPOPROTEINS A; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; LIFE STYLE; PATIENT EDUCATION AS TOPIC; RISK FACTORS;

EID: 35348856847     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01509.x     Document Type: Review

References (43)

1. Lamarche B, Tchernof A, Moorjani S et al. Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec cardiovascular study. Circulation 1997 95 : 69 75.
2. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988 260 : 1917 21.
3. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
4. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006 48 : 438 45.
5. Bruckert E, Baccara-Dinet M, McCoy F, Chapamn J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005 21 : 1927 34.
6. Rubins HB, Robins SJ, Collins D et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995 75 : 1196 201.
7. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 62 : 707 14.
8. Asztalos BF, Demissie S, Cupples A et al. LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis 2006 188 : 59 67 G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 124 (Suppl. S11 20.
9. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989 79 : 8 15.
10. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997 17 : 107 13.
11. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshina H. The inverse relationship between serum total high-density lipoprotein cholesterol and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 2006 184 : 143 50.
12. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001 358 : 2026 33.
13. Sharrett AR, Ballantyne CM, Coady SA et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001 104 : 1108 13.
14. Yusuf S, Hawken S, ôunpuu S et al. on behalf of the INTERHERT study investigators Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries. Lancet 2005 366 : 1640 49.
15. Gotto AM, Whitney E, Stein EA et al. AFCAPS Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000 101 : 477 84.
16. Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 2006 151 : 755.e1 e6.
17. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. Circulation 1992 86 : 839 848.
18. Moorjani S, Gagné C, Lupien PL, Brun D. Plasma triglycerides related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia. Metabolism 1986 35 : 311 6.
19. Assmann G, Von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 1993 87 (4 Suppl. III28 34.
20. Ayyobi AF, McGladdery SH, Chan S, Mancini GBJ, Hill JS, Frihlich JJ. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis 2004 177 : 361 6.
21. Rust S, Rosier M, Funke H et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999 22 : 352 5.
22. Franceschini G, Calabresi L, Chiesa G et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999 19 : 1257 62.
23. Bruckert E. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Atherosclerosis 1997 128 : 121 8.
24. Glueck CJ, Fallat F, Millett P, Gartside R, Elston RC, Go RCP. Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds. Metabolism 1975 24 : 1243 65.
25. Barzilai N, Atzmon G, Schechter C et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003 290 : 2030 40.
26. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004 350 : 1505 15.
27. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006 111 : 893 908.
28. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall Nat Clin Pract Cardiovasc Med 2006 3 : 144 53.
29. Birjmohun RS, Hutten BA, Kastelein JPD, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005 45 : 185 97.
30. Bruckert E, De Gennes JL, Malbecq W, Baigts F. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and mixed hyperlipidemia. Clin Cardiol 1995 18 : 621 9.
31. Guérin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalises the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996 16 : 763 72.
32. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993 100 : 91 102.
33. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987 317 : 1237 45.
34. Robins SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 2001 88 : 19N 23N.
35. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Disease Study. JAMA 1988 260 : 641 51.
36. Otvos JD, Collins D, Freedman DS et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006 113 : 1556 63.
37. The FIELD investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 366 : 1849 61.
38. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005 165 : 1154 60.
39. Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006 60 : 442 9.
40. McCormack PL, Keating GL. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005 65 : 2719 40.
41. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005 95 : 360 6.
42. Nissen SE, Nicholls SJ, Sipahi I et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 295 : 1556 65.
43. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003 290 : 2292 300.